Workflow
Months after cancer drug trial, Merus agrees to be bought at 41% premium
MerusMerus(US:MRUS) MarketWatchยท2025-09-29 09:34

Core Viewpoint - Merus has agreed to be acquired at a 41% premium following a successful trial of a cancer drug [1] Company Summary - The acquisition reflects confidence in Merus's recent positive trial results for its cancer drug, which may enhance its market position and investor interest [1] Industry Summary - The deal highlights ongoing consolidation trends in the biopharmaceutical industry, particularly in the oncology sector, as companies seek to bolster their drug pipelines through strategic acquisitions [1]